Led · Equity · Mar 2026

Founded in December 2022 in Ras Bufontas Free Zone, Qatar, Skydrops operates the region's first atmospheric water generation (AWG) plant and offers premium reusable water packaging. The company captures humidity from the air and converts it into clean, mineralized drinking water using technology supplied through a partnership with U.S.-based Tsunami Products. Skydrops is expanding distribution across retail, hospitality, corporate, and institutional channels and is preparing for a London Stock Exchange listing. It plans to scale production facilities and integrate additional technology as part of its international growth into the GCC, North America, and Asia. Financially, the company has secured an up-to-£20 million investment commitment from GEM Global Yield LLC to support those expansion efforts.

Participated · Series B · Jan 2026

Neowise (新景智源生物科技) focuses on the discovery and development of TCR-T immunotherapies aimed at solid tumors. The company has built a proprietary high-throughput, high-sensitivity target-antigen/TCR discovery platform (CAST®) that combines AI computation with experimental validation to rapidly identify high-affinity, tumor-specific TCR sequences. Its lead candidate, NW-101C, targets PRAME and is the first domestic therapy against this antigen to reach clinical trials, currently in a Phase I registration study across multiple late-stage solid tumors. A second candidate, NW-301V, targets the KRAS G12V mutation and delivered an objective response rate of 50% and a disease control rate of 100% in an early trial involving 14 evaluable colorectal and pancreatic cancer patients, with no dose-limiting toxicities observed. Over the past two years the company has advanced two programs into the clinic, validating its platform capabilities. Proceeds from the latest financing will fund further clinical development of these core assets and advance multiple preclinical programs, while supporting commercialization and international expansion efforts. The firm has received continued backing from existing investors alongside new institutional support, underscoring confidence in its pipeline and platform.

Led · Equity · Feb 2024

RELIEF THERAPEUTICS Holding SA positions itself in biotech with a focus on healthcare and rare-disease therapeutics, as indicated in its LinkedIn post. The company announced it secured a CHF 50 million capital commitment from GEM through the renewal of its share subscription facility. The transaction is presented as a renewal of an existing share subscription facility rather than a newly announced equity round. The LinkedIn post included the company tickers $RLF $RLFTF $RLFTY and used hashtags referencing biotech, healthcare, and rare disease. Social-media commenters raised questions about whether a proposed 400:1 reverse share split and plans to list on Nasdaq were affected by the news. The post did not disclose operating metrics, valuation, past financing rounds, founding year, or location. Relief Therapeutics is a clinical-stage biotechnology company focused on developing treatments for conditions associated with degeneration of the peripheral nervous system (neuropathy). Its lead drug candidate is atexakin alfa. The company intends to use newly raised funds to support clinical development activities for atexakin alfa. Relief secured rights to the underlying intellectual property and global commercialization from Merck KGaA via a licensing agreement dated August 2015. The company is led by CEO Gaël Hédou, COO Michel Dreano, and CSO Yves Sagot, and was incorporated in May 2013 in Geneva, Switzerland. Financially, Relief has begun its €2.5M Series A with receipt of the first tranche from Global Emerging Markets.

Led · Equity · Jun 2023

Aquaback Technologies develops patented, energy-efficient wastewater treatment systems that use standardized distillers to recycle the heat of vaporization. The company says this approach lowers the cost of recycling wastewater and can produce clean distilled water for less than most consumers pay for potable water while eliminating contamination from wastewater disposal. Its distillers can be deployed in small decentralized treatment uses or in large utility-scale installations. Target market applications include industrial wastewater treatment and recycling, point-of-entry safe water supply, recycling contaminated source water for direct potable use, advanced treatment by water utilities to remove emerging contaminants, production of distilled water as feed water for electrolyzers to produce green hydrogen, and advanced treatment of septic and sewage to mitigate nitrogen pollution. Aquaback is led by President and CEO Scott C. Newquist. The company has secured financing from an investor to support a planned public listing.